“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

The decision came Tuesday from US District Judge Melissa DuBose in response to a lawsuit filed by attorneys general from 19 states and the District of Columbia, the Associated Press reported. DuBose ...

HealthDay News — Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations decreases ...

The Food and Drug Administration (FDA) has approved Tyzavan ™ (vancomycin injection, USP), a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various ...

The wearable, transcutaneous neurostimulation device delivers personalized therapy using a proprietary AI algorithm.